Beneficial ownership — 13D / 13G
87,314 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| Dr. Ehud Geller | PRFX PRF Technologies Ltd. | 13G/A | 19.85% | Dec 31, 2023 | 2y |
| Merck Healthcare KGaA, Darmstadt Germany an affiliate of Merck KGaA, Darmstadt, Germany | MLTX MoonLake Immunotherapeutics | 13G/A | 4.7% | Dec 31, 2023 | 2y |
| Marco Ferri | MKTW Marketwise, Inc. | 13G | 6.7% | Dec 31, 2023 | 2y |
| PURA VIDA INVESTMENTS, LLC | LYRA Lyra Therapeutics, Inc. | 13G/A | 3.06% | Dec 31, 2023 | 2y |
| TEACHERS INSURANCE & ANNUITY ASSOCIATION OF AMERICA | NCDL Nuveen Churchill Direct Lending Corp. | 13G/A | 12.42% | Dec 31, 2023 | 2y |
| Zdravka Medarova | RNAZ Transcode Therapeutics, Inc. | 13G/A | 0.4% | Dec 31, 2023 | 2y |
| Amber Mason | MKTW Marketwise, Inc. | 13G | 9.1% | Dec 31, 2023 | 2y |
| BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC | HERZ Herzfeld Credit Income Fund, Inc | 13G | 12.4% | Dec 31, 2023 | 2y |
| Christy Lovig | AVNI Arvana Inc | 13G | 5.56% | Jan 3, 2023 | 2y |
| Kerri Ann Hulet | AVNI Arvana Inc | 13G/A | 5.56% | Jan 3, 2023 | 2y |
| Charles Youakim | SEZL Sezzle Inc. | 13D | 43.6% | Jun 11, 2021 | 2y |
| PERCEPTIVE ADVISORS LLC | LYRA Lyra Therapeutics, Inc. | 13D/A | 24.3% | Feb 14, 2024 | 2y |
| Luxor Capital Group, LP | TFIN Triumph Financial, Inc. | 13G/A | 5.2% | Feb 14, 2024 | 2y |
| Jason Kelly | DNA Ginkgo Bioworks Holdings, Inc. | 13D/A | 5% | Feb 14, 2024 | 2y |
| Edward W. Cochran | CFBK Cf Bankshares Inc. | 13D/A | 6.5% | Feb 14, 2024 | 2y |
| TTWFGP LLC | WLKP Westlake Chemical Partners LP | 13D/A | 44.1% | Feb 14, 2024 | 2y |
| Umbrella Global Energy S.A. | TURB Turbo Energy, S.A. | 13D | 90.96% | Feb 14, 2024 | 2y |
| 5AM Ventures VI, L.P. | VOR Vor Biopharma Inc. | 13D/A | 9.4% | Feb 14, 2024 | 2y |
| Reshma P. Shetty | DNA Ginkgo Bioworks Holdings, Inc. | 13D/A | 10.5% | Feb 14, 2024 | 2y |
| Thomas W. Powell | POWL Powell Industries Inc | 13D/A | 20.5% | Feb 14, 2024 | 2y |
| Gayle G. Green | GRC Gorman Rupp Co | 13D | 9.6% | Feb 14, 2024 | 2y |
| Goal Acquisitions Sponsor LLC | PUCK Goal Acquisitions Corp. Common Stock | 13D/A | 54.48% | Feb 14, 2024 | 2y |
| Jeffrey S. Gorman | GRC Gorman Rupp Co | 13D | 10.5% | Feb 14, 2024 | 2y |
| StepStone Group LP | NEUE NeueHealth, Inc. | 13D/A | 6.8% | Feb 14, 2024 | 2y |
| Value Base Ltd. | VLN Valens Semiconductor Ltd. | 13G/A | 10.07% | Feb 13, 2024 | 2y |
| JANE STREET GROUP, LLC | CVNA Carvana Co. | 13G/A | 3.8% | Feb 13, 2024 | 2y |
| Jill Foss Watson | CACC Credit Acceptance Corp | 13D/A | 15.1% | Feb 13, 2024 | 2y |
| Robert L. Dumont | IDR Idaho Strategic Resources, Inc. | 13G | 4.38% | Feb 13, 2024 | 2y |
| Notch View Capital Management, LLC | FREE Whole Earth Brands, Inc. Class A Common Stock | 13D/A | 0% | Feb 13, 2024 | 2y |
| Rubric Capital Management LP | XPER Xperi Inc. | 13D/A | 8.6% | Feb 13, 2024 | 2y |
| Monte M. Brem | STEP StepStone Group Inc. | 13D/A | 49.1% | Feb 12, 2024 | 2y |
| BFI Co., LLC | PAHC Phibro Animal Health Corp | 13D/A | 49.9% | Feb 12, 2024 | 2y |
| The Column Group III, LP | TNYA Tenaya Therapeutics, Inc. | 13D/A | 17.7% | Feb 12, 2024 | 2y |
| RA CAPITAL MANAGEMENT, L.P. | HOWL Werewolf Therapeutics, Inc. | 13D/A | 15.2% | Feb 12, 2024 | 2y |
| Family Trading Inc. | TOPS Top Ships Inc. | 13D/A | 63.35% | Feb 12, 2024 | 2y |
| Charles Ashton Newhall | STEP StepStone Group Inc. | 13D/A | 5.3% | Feb 12, 2024 | 2y |
| Michael Graves | EGRX Eagle Pharmaceuticals, Inc. | 13D | 1.8% | Feb 12, 2024 | 2y |
| VERIZON COMMUNICATIONS INC | BMR Beamr Imaging Ltd. | 13G | 0% | Feb 12, 2024 | 2y |
| Saba Capital Management, L.P. | STHO Star Holdings | 13G | 5.2% | Feb 9, 2024 | 2y |
| Van Herk Investments B.V. | PRQR ProQR Therapeutics N.V. | 13G/A | 10.1% | Feb 9, 2024 | 2y |
| Peter Hebert | EVLV Evolv Technologies Holdings, Inc. | 13D/A | 1.1% | Feb 8, 2024 | 2y |
| SPRING CREEK CAPITAL LLC | ALCYF Alchemy Investments Acquisition Corp 1 | 13G | 5.42% | Feb 8, 2024 | 2y |
| Fung Ching Wong | LSBWF LakeShore Biopharma Co., Ltd. | 13D | 0.23% | Feb 7, 2024 | 2y |
| Bain Capital Life Sciences Opportunities III, LP | KYTX Kyverna Therapeutics, Inc. | 13G | 7.4% | Feb 7, 2024 | 2y |
| Oxus Capital PTE. LTD. | BRLS Borealis Foods Inc. | 13D | 46.3% | Feb 7, 2024 | 2y |
| Reza Soltanzadeh | BRLS Borealis Foods Inc. | 13D | 17.12% | Feb 7, 2024 | 2y |
| Barthelemy Helg | BRLS Borealis Foods Inc. | 13D | 14.99% | Feb 7, 2024 | 2y |
| Fennell Todd W. | PRTA Prothena Corp Public Ltd Co | 13G | 5.85% | Feb 5, 2024 | 2y |
| MILLENNIUM MANAGEMENT LLC | ACRS Aclaris Therapeutics, Inc. | 13G | 5.3% | Feb 5, 2024 | 2y |
| SCULLY WILLIAM P | PRTA Prothena Corp Public Ltd Co | 13G | 6.53% | Feb 5, 2024 | 2y |